Despite the poor prognosis of case #2, his blast count was only 5-7%, which is consistent with findings that the prognosis of MDS or AML cases with MECOM rearrangements is not dependent on blast count (11). The gene discussed is MECOM; the disease is acute myeloid leukemia.